RETRACTED: Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways (Retracted article. See SEP, 2022)

被引:83
作者
Liu, Sha [1 ,2 ]
Gao, Guozhen [2 ]
Yan, Dexiong [2 ]
Chen, Xiangjun [2 ]
Yao, Xingwei [2 ]
Guo, Shuzhong [1 ]
Li, Guirong [3 ]
Zhao, Yu [4 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Plast & Reconstruct Surg, Xian 710032, Peoples R China
[2] 253rd Hosp PLA, Dept Burn & Plast Surg, Hohhot 010051, Inner Mongolia, Peoples R China
[3] Fourth Peoples Hosp Shaanxi Prov, Dept Otolaryngol Head & Neck Surg, 512 East Xianning Rd, Xian 710043, Shaanxi Provinc, Peoples R China
[4] Fourth Mil Med Univ, Xijing Hosp, Dept Otolaryngol Head & Neck Surg, 127 West Changle Rd, Xian 710032, Shaanxi Provinc, Peoples R China
来源
CANCER MEDICINE | 2017年 / 6卷 / 04期
基金
中国国家自然科学基金;
关键词
MAPK; melanoma; miR-145-5p; NRAS; METASTATIC MELANOMA; CANCER CELLS; TUMOR; BRAF; GROWTH; RAS; SUPPRESSES; MUTANT; OVEREXPRESSION; MICRORNA-145;
D O I
10.1002/cam4.1030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We aimed to detect the effects of miR-145-5p on the cell proliferation, apoptosis, migration, and invasion in NRAS-mutant, BRAF-mutant, and wild-type melanoma cells, in order to figure out the potential mechanisms and provide a novel therapeutic target of melanoma. RT-qPCR and western blot were used to detect the expression of miR-145-5p and NRAS in melanoma tumor tissues and cells, respectively. Luciferase assay was performed to determine whether miR-145-5p directly targeted NRAS. After transfecting miR-145-5p mimics, miR-145-5p inhibitors, NRAS cDNA and NRAS siRNA into CHL-1, VMM917 and SK-mel-28 cells, functional assays were used to detect the proliferation, apoptosis, invasion and migration, including MTT, flow cytometry, Transwell and wound healing assays. In addition, xenograft models in nude mice were also conducted to verify the role of miR-145-5p in vivo. MiR-145-5p was able to suppress proliferation, invasion, and migration of VMM917 and CHL-1 cells and induce apoptosis by inhibiting MAPK and PI3K/AKT pathways. However, aberrant expression of miR-145-5p and NRAS has little impact on the viability and metastasis of BRAF-mutant melanoma. The higher expression of miR-145-5p in xenograft models repressed the VMM917-induced and CHL-1-induced tumor growth observably and has little effect on SK-mel-28-induced tumor growth which was consistent with the results in vitro. Through targeting NRAS, miR-145-5p could suppress cell proliferation, invasion, and migration and induce apoptosis of CHL-1 and VMM917 melanoma cells by inhibiting MAPK and PI3K/AKT pathways.
引用
收藏
页码:819 / 833
页数:15
相关论文
共 47 条
  • [1] Molecular drivers of cellular metabolic reprogramming in melanoma
    Abildgaard, Cecilie
    Guldberg, Per
    [J]. TRENDS IN MOLECULAR MEDICINE, 2015, 21 (03) : 164 - 171
  • [2] Effect of probe characteristics on the subtractive hybridization efficiency of human genomic DNA
    Archer M.J.
    Long N.
    Lin B.
    [J]. BMC Research Notes, 3 (1)
  • [3] Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
    Batus, Marta
    Waheed, Salman
    Ruby, Carl
    Petersen, Lindsay
    Bines, Steven D.
    Kaufman, Howard L.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2013, 14 (03) : 179 - 194
  • [4] BOS JL, 1989, CANCER RES, V49, P4682
  • [5] PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
    Britten, Carolyn D.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1395 - 1409
  • [6] Emerging insights into resistance to BRAF inhibitors in melanoma
    Bucheit, Amanda D.
    Davies, Michael A.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2014, 87 (03) : 381 - 389
  • [7] Mutations of the BRAF gene in human cancer
    Davies, H
    Bignell, GR
    Cox, C
    Stephens, P
    Edkins, S
    Clegg, S
    Teague, J
    Woffendin, H
    Garnett, MJ
    Bottomley, W
    Davis, N
    Dicks, N
    Ewing, R
    Floyd, Y
    Gray, K
    Hall, S
    Hawes, R
    Hughes, J
    Kosmidou, V
    Menzies, A
    Mould, C
    Parker, A
    Stevens, C
    Watt, S
    Hooper, S
    Wilson, R
    Jayatilake, H
    Gusterson, BA
    Cooper, C
    Shipley, J
    Hargrave, D
    Pritchard-Jones, K
    Maitland, N
    Chenevix-Trench, G
    Riggins, GJ
    Bigner, DD
    Palmieri, G
    Cossu, A
    Flanagan, A
    Nicholson, A
    Ho, JWC
    Leung, SY
    Yuen, ST
    Weber, BL
    Siegler, HF
    Darrow, TL
    Paterson, H
    Marais, R
    Marshall, CJ
    Wooster, R
    [J]. NATURE, 2002, 417 (6892) : 949 - 954
  • [8] Targeting ras signalling pathways in cancer therapy
    Downward, J
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 11 - 22
  • [9] miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells
    Dynoodt, Peter
    Speeckaert, Reinhart
    De Wever, Olivier
    Chevolet, Ines
    Brochez, Lieve
    Lambert, Jo
    Van Gele, Mireille
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 42 (04) : 1443 - 1451
  • [10] NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
    Fedorenko, I. V.
    Gibney, G. T.
    Smalley, K. S. M.
    [J]. ONCOGENE, 2013, 32 (25) : 3009 - 3018